
Building a resilient research architecture and capability to protect us all

Dr Ibrahima Soce Fall Assistant Director General Health Emergencies Operations WHO)





Monkeypox is a viral zoonotic disease endemic in more than 9 African countries



Therefore it is critical that we support their control efforts with renewed vigor!

Control here is a critical step to prevent importation in other countries and importantly to reduce the burden in the endemic countries





WHO has and is currently updating/developing a number of tools to support the control efforts

Laboratory testing for the monkeypox virus

Interim guidance

23 May 2022



Key points

- The goal of the global response to the multi-country outbreak of monkeypox is to stop the outbreak.
- Any individual that meets the suspected case definition for monkeypox should be offered testing.
- . The recommended specimen type for diagnostic confirmation of monkeypox in suspected cases is skin lesion material, including swabs of lesion exudate, roofs from more than one lesion, or lesion crusts.
- · Laboratory confirmation of specimens from a suspected case is done using nucleic acid amplification testing (NAAT), such as realtime or conventional polymerase chain reaction (PCR). NAAT can be generic to orthopoxvirus (OPXV) or specific to
- · All manipulations in laboratory settings of specimens originating from suspected, probable or confirmed cases of monkeypox should be conducted according to a risk-based approach.
- In addition to NAAT, sequencing is useful to determine virus clade and to understand epidemiology. Member States are strongly encouraged to share MPXV genetic sequence data in available and publicly accessible databases.
- . Member States are requested to immediately notify WHO under the International Health Regulations (IHR) 2005 of positive laboratory results, including a generic OPXV laboratory test that awaits confirmation.
- . WHO can assist Member States to access testing through referral. If the need arises, Member States can contact the relevant WHO Regional Office.

Surveillance, case investigation and contact tracing for Monkeypox

Interim guidance 22 May 2022



Key points

- There is currently a multi-country outbreak of monkeypox in several regions of the world, the full extent and impact of which remains unclear. The overall goal of surveillance, case investigation and contact tracing in this context is to break chains of human to human transmission and stop the outbreak.
- The key objectives of surveillance and case investigation for monkeypox in the current context are to rapidly identify cases and clusters in order to provide optimal clinical care; to isolate cases to prevent further transmission; to identify and manage contacts; to protect frontline health workers; and to tailor effective control and prevention measures.
- The situation is rapidly evolving and WHO expects there will be more cases of monkeypox identified as surveillance expands in non-endemic countries. Immediate actions focus on: informing those who may be most at risk for monkeypox virus (MPXV) infection with accurate information; stopping further spread; and protecting frontline workers.
- Clinicians should report suspected cases immediately to public health authorities.
- Probable and confirmed cases of monkeypox should be reported immediately to WHO through IHR national focal points (NFPs) under the International Health Regulations (IHR 2005)
- . If monkeypox is suspected, case investigation should consist of clinical examination of the patient with appropriate PPE, questioning the patient about possible sources of infection, and safe collection and dispatch of specimens for MPXV laboratory examination.
- In the current context, as soon as a suspected case is identified, contact identification and contact tracing
- . Contacts should be monitored at least daily for the onset of any signs/symptoms for a period of 21 days from

Monkeypox protective measures









Prote

Wher





Public health advice for gay, bisexual and other men who have sex with men on the recent outbreak of monkeypox

An outbreak of a disease called monkeynox is currently taking place in many countries that do not typically have cases. This can be concerning, especially for people whose loved ones or been identified through sexual health clinics in communities of gay, bisexual and other men who

How to use this document: is not limited to men who have sex with men Anyone who has close contact with someone who is infectious is at risk. However, given that learning about monkeypox, how it spreads and how to notect yourself will help ensure that as few people as possible are affected and that the

This document contains information on how have symptoms and how to protect yourself and others. It can be used by community leaders. social events and parties to inform and engage

Information on this outbreak is changing rapidly as we learn more. Check who.int for the most up to date information.

What you need to know:

These are some examples. Other guidance are in the pipeline regarding clinical management, vaccine strategies etc.







The entire of WHO is generating daily epidemiological updates, guidance and assessing the level of risk regularly

Multi-country monkeypox outbreak in non-endemic countries: Update

29 May 2022







Epidemiological Alert in non-endemic countries

20 May 2022

Given the occurrence of cases of monkeypox in countries within and outside of the Region of the Americas, the Pan American Health Organization / World Health Organization (PAHO/WHO) shares with its Member States a series of considerations in relation to the identification of cases, the isolation, identification and follow-up of contacts, the clinical management, and the prevention and control of healthcare-associated infections. Guidance regarding available treatment and vaccines is also provided.

Situation Summary

On 15 May 2022, the World Health Organization (WHO) was notified of 4 confirmed cases of Monkeypox ICD-10 804 (7. 8) monkeypox from the United Kingdom, Two days later, two other countries reported cases: Portugal and Sweden. All of the cases had no reported history of travel to an area endemic for monkeypox and there was no epidemiological link between the cases reported in different countries. As of 20 May 2022, 11 countries have reported cases: Australia, Belaium, Canada, France, Germany, Italy, Portugal, Spain, Sweden, the United Kingdom, and the United States of

In the Region of the Americas, 3 cases of monkeypox have been reported, in Canada (2

Monkeypox is commonly found in Central and West Africa, where there are tropical forests

mankeypox virus, which belongs to the virus (which causes smallpox). There are two the Congo Basin (Central African) strain and ne West African strain appear to cause less severe disease compared to the Congo Basin Technical Brief (interim) and Priority Actions: Enhancing Readiness for monkeypox in WHO South-East Asia Region

WHO Regional Office for South-East Asia 28 May 2022




Summary

 Since 13 May 2022, cases of monkeypox have been reported to WHO from Member States that are not endemic for monkeypox virus.

ecommended priority actions

- Surveillance: Clinicians' awareness is the key for detection of monkey pox. Hence, sensitization of clinician working at relevant health services at public and private sectors is critical. Once a suspected case is identified, clinicians should report immediately to public health authorities; the samples be referred for laboratory testing: and case investigation and contact tracing should be initiated.
- Laboratory testing: Laboratory will confirm monkey pox infection on the basis of nucleic acid amplification testing (NAAT), using real-time or conventional polymerase chain reaction (PCR). Planning for genomic sequencing for characterization of monkey pox viruses and sharing data for public health decision making are important
- Clinical management & Infection Prevention and Control (IPC): Health workers carring for suspected or confirmed patients need to implement standard, contact and droplet precautions. It is necessary to isolate patients and continue transmission-based precautions until resolution of symptoms. WHO interim guidance on clinical management and IPC is pending.
- Vaccination: Based on previous SAGE recommendations, Member States may consider vaccination of close contacts as post-exposure prophylaxis or pre-exposure vaccination of laboratory personnel and health workers. WHO interim guideline for vaccination for monkey pox prevention and control is pending
- Risk communication and community engagement: Proactively communicating information related to





Health topics v Countries v Newsroom v Data and evidence About us

WHO is supporting African countries to strengthen monkeypox surveillance and response actions

Brazzaville, 31 May 2022 - Seven African countries have cumulatively reported to the World Health Organization (WHO) nearly 1400 monkeypox cases (1392 suspected, 44 confirmed) so far this year. This case count is for the year up until mid-May and is based on preliminary reports.

The cases have been reported from Cameroon, Central African Republic, the Democratic Republic of the Congo, Liberia, Nigeria, the Republic of the Congo and Sierra Leone. The number of cases in 2022 are slightly fewer than half of cases reported in 2021.

While the virus has not spread to new non-endemic countries in Africa, within countries with outbreaks, the virus has been expanding its geographic reach in recent years. For example, until 2019, monkeypox in Nigeria was reported mainly in the south of the country but since 2020, the virus has moved into central, eastern and northern parts of the country.



Key priorities

- 1. **CONTAIN**: At present the outbreak in non-endemic countries is still containable. WHO encourages countries to
 - Raise awareness
 - Detect cases: enhance clinical recognition of the disease to ensure early detection of cases and isolation of patients
 - Stop chains of transmission: intensified surveillance in certain population groups, cluster investigation and contact tracing
 - Protect Health care workers and prevent transmission in health care settings (PPE, Infection prevention and control)

 To do:
 - adapt and strengthen existing surveillance systems, laboratory and testing capacities
 - Utilize the Case Reporting Form (CRF) once published to better understand the clinical characterization across regions
 - If using therapeutics: collect standardized data or use clinical trial protocols to understand effectiveness
 - Use, adapt and strengthen care pathways with appropriate IPC measures to prevent onwards transmission and access to symptomatic care elements such as good primary care, pain control and skin care.





Key priorities (cont)

- **2. Ensure effective communication** strategies to **avoid stigmatisation** of certain population groups and reduce impact on societies, travel and trade. Continue to communicate what we know, what is being done to respond and continue to update and publish products as data becomes available.
- **3. Risk based strategies:** Utilize countermeasures and Public health interventions based on **need, risk and benefit** including basic public health interventions (therapeutics, vaccines, testing, diagnostics and sequencing)

 Apply measures **commensurate to the risk** (for instance promote safe gatherings)

4. Global Collaboration

- Continue sharing information, diagnostic resources and data. Use standardised protocols to enable comparison of data between countries
- > Support the development of global mechanisms to ensure equitable access to countermeasures (vaccine, therapeutics, diagnostics) based on public health needs . WHO virtual stockpile
- Accelerate the research agenda for monkeypox
- **5. Strengthen One Health** approach in endemic countries





Key priorities (cont)



6. Identify the knowledge gaps and accelerate the research agenda





Identify the knowledge gaps and accelerate the research agenda



During TODAYS consultation with your support will review the available evidence in terms of:

- Our understanding the dynamics of monkeypox transmission, epidemiology and the clinical characteristics of the disease.
- Available evidence regarding therapeutics, diagnostics and vaccines licensed and under development.
- Novel approaches for further evaluation of monkeypox therapeutics and vaccines.
- Countries perspectives in terms of research priorities and opportunities.





Identify the knowledge gaps and accelerate the research agenda



EXPECTED OUTCOMES

Baseline information to outline **a Research Roadmap** enumerating knowledge gaps, and outlining priority research

A defined list of **next steps to address the above** for the scientific community in general and for WHO in particular





Thank you



